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CASE PRESENTATION
A 17-year-old boy presented to the Emergency Room
with abdominal pain, which began 7 days prior to his
admission. The pain was accompanied by nausea,
vomiting, and diarrhea, which he attributed to food
poisoning. He began experiencing pain in both wrists
3 days prior to his visit. He denied history of fevers,
chills, shortness of breath, dysuria, or rash. He admitted
to experiencing a low level of energy after an upper
respiratory tract infection 10 days prior to admission.
His only medications at home were sertraline,
resperidone, and methylphenidate for depression, which
he was taking for 1 year prior to admission. Patient
had been in foster care all his life.
On physical examination, he was a well-developed,
well-nourished boy, with body temperature of 981F, heart
rate of 122 beats per min1, blood pressure of 156/
83 mm Hg, respiratory rate of 20 min1, and a nonpruritic,
nonpetechial, maculopapular rash on his left elbow and
both lower extremities. He had swelling over both eyelids.
He had diffuse abdominal tenderness and guaiac-positive
stool, which turned to melena by hospital day 7.
His laboratory workup is shown in Table 1.
To summarize, on presentation, blood urea nitrogen
was 17 mg per 100 ml (6.1 mmol l1) (normal range:
10–30 mg per 100 ml or 3.6–10.7 mmol l1) and serum
creatinine was 0.8 mg per 100 ml (60mmol l1) with a GFR
estimated at 160 ml min1 by Schwartz formula. Liver
function tests, amylase and lipase levels were normal.
Amylase (normal range: 40–128 U l1) and lipase levels
(normal range: 7–60 U l1) rose to 165 and 79 U l1,
respectively on day 14 with aspartate aminotransferase
(normal range: 1–40 U l1), alanine aminotransferase
(normal range: 1–45 U l1), and g-glutamyltransferase
(normal range: 9–54 U l1) of 53, 75, and 211 U l1,
respectively, on day 16.
Initial urinalysis was normal. Urinalysis on day 9
showed moderate blood and 2þ protein on dipstick with
microscopic examination showing 30–40 red blood cells
(RBCs) per high-power field. Proteinuria steadily increased
from 0.6 g per day on day 9 to 3.5 g per day on day 16.
Serologic test results were negative for antinuclear
antibody, antineutrophil cytoplasmic antibody, rheumatoid
factor, syphilis, Epstein–Barr virus IgM, HIV antibody,
hepatitis B surface antigen, and hepatitis C antibody.
Antistreptolysin O antibody titer was 400 IU l1 on
admission rising to 800 IU l1 on day 14. Complement
3 (C3) and complement 4 (C4) levels are given in the table.
Computer tomography of the abdomen showed edema
and thickening of the jejunum with other viscera reported
as normal (Figure 1a). Skin biopsy showed evidence of
leukocytoclastic vasculitis (Figure 1b). Echocardiography
performed during his hospital stay for the complaints of
shortness of breath and chest pain showed evidence of left
ventricle dilatation with low normal ejection fraction and
prominent coronary arteries. Renal biopsy was performed.
RENAL BIOPSY FINDINGS
Light microscopy evaluation revealed two cores of renal
cortex containing 10 glomeruli, none of which were globally
sclerotic. Glomeruli displayed mild diffuse and segmental
mesangial hypercellularity. Superimposed on these mesangial
proliferative features, three glomeruli displayed segmental
endocapillary proliferation with focal infiltrating monocytes
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and neutrophils. Two glomeruli contained small cellular
crescents associated with fibrin extravasation in Bowman’s
space (Figure 1c). There was no tubular atrophy, interstitial
fibrosis, or inflammation. No red blood cell casts were identi-
fied. Vessels appeared unremarkable. No vasculitis was seen.
Immunofluorescence revealed 3þ granular to semilinear
global glomerular mesangial staining for IgA (Figure 1d),
with 1 to 2þC3, negative IgG, negative IgM, negative C1q,
2þ k, and 3þ l. No vascular staining was seen. By electron
microscopy, the mesangial areas were globally expanded by
mild increase in mesangial cell number and matrix contain-
ing abundant small- to medium-sized mesangial electron
dense deposits. There was segmental endocapillary hyper-
cellularity including a few infiltrating neutrophils. No
electron-dense deposits involving the peripheral capillaries
were identified. No endothelial tubuloreticular inclusions
were seen. There was mild-to-moderate effacement of foot
processes involving approximately 30% of the glomerular
capillary surface area. No tubulointerstitial or vascular
electron-dense deposits were identified.
PATHOLOGIC DIAGNOSIS
Diffuse mesangial and focal endocapillary proliferative
glomerulonephritis with focal cellular crescents, consistent
with Henoch–Scho¨nlein purpura (HSP) nephritis.
CLINICAL FOLLOW-UP
Treatment was started with pulse intravenous methylpredni-
solone 1000 mg per day for 3 days. The patient was then
started on prednisone 60 mg orally once a day and 10 mg of
fosinopril orally once daily with a decrease in proteinuria to
less than a gram per day at follow-up after 2 months. Renal
function remained normal at 3 months follow-up.
DISCUSSION
Henoch–Scho¨nlein purpura is the most common systemic
small vessel vasculitis in children generally between 2 and 15
years of age with 50% of the cases manifesting before the age
of 5 years. Renal disease is more likely to occur and be more
severe in older children. It has a slight male preponderance.
From the limited epidemiologic data, HSP seems to be far
less common in adults. There may be seasonal variations with
most cases in the fall and winter. It is seen infrequently in
African-American individuals. It is characterized by the tissue
deposition of IgA-containing immune complexes.1 The
etiology of HSP remains unknown though infections and
drugs have been implicated as triggers in over half of the
patients. The pathogenesis of this disorder may be similar to
that of IgA nephropathy, that is, secondary to defective
glycosylation and decreased clearance of IgA1, and increased
binding and deposition of mesangial IgA with co-deposition
Table 1 | Laboratory data
a. Blood count values On presentation Normal range
White blood cell count 16.0 109 l1 4.3–10.8 109 l1
Polymorphonuclear
cells
84.80% 48–82%
Platelet count 345 109 l1 150–500 109 l1
b.
Serum chemistry
values On presentation Day 14 Day 16 Normal range
Serum creatinine 0.8 mg per 100 ml
(60 ı`mol l1)
0.6 mg per 100 ml
(46 ı`mol l1)
0.4 mg per 100 ml
(31 ı`mol l1)
0.1–1.0 mg per 100 ml
(9–88 ı`mol l1)
Blood urea nitrogen 17 mg per 100 ml
(6.1 mmol l1)
19 mg per 100 ml (
6.8 mmol l1)
23 mg per 100 ml
(8.2 mmol l1)
3–25 mg per 100 ml
(1.1–8.9 mmol l1)
Amylase 81 U l1 169 U l1 234 U l1 40–128 U l1
Lipase 17.2 U l1 79.8 U l1 130 U l1 7–60 U l1
Aspartate
aminotransferase
22 U l1 31 U l1 53 U l1 1–40 U l1
Alanine
aminotransferase
11 U l1 38 U l1 75 U l1 1–45 U l1
g-Glutamyltransferase N/A 110 U l1 211 U l1 9–54 U l1
Antistreptolysin O
antibody titer
400 IU l1 800 IU l1 800 IU l1 p200 IU l1
Complement 3 89 mg per 100 ml 70 mg per 100 ml 92 mg per 100 ml 90–180 mg per 100 ml
Complement 4 26.5 mg per 100 ml 22.5 mg per 100 ml 25.3 mg per 100 ml 10–40 mg per 100 ml
c. On presentation Day 9 Day 16
Urinalysis Normal Moderate blood and 2+
protein, microscopic
examination showing
30–40 red blood cells per
high-power field
Proteinuria 0 0.6 g per 100 ml per day 3.5 g per 100 ml per day
N/A, not available.
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of C3 in some cases, which may result in low serum C3 levels.
A low C3 level is, however, very rare in HSP. HSP is
characterized by the following tetrad of symptoms, which
may occur in any order: rash, arthralgias, abdominal pain,
and renal disease (Table 2), with other organ involvement
being uncommon.
Renal manifestations of HSP
Renal involvement is one of the serious manifestations
of HSP. Common renal manifestations are hematuria and
proteinuria, which may be in the nephrotic range. Persistent
disease is uncommon, especially in children. A retrospective
analysis of an unselected population of patients with
HSP including 46 adults and 116 children showed that the
disease is more severe in adults with higher frequency of
renal involvement.2 However, the authors found that the
final outcome was good in both groups.2 A retrospective
analysis of a cohort of 250 adults with HSP diagnosed on
renal biopsy with a follow-up of 15 years showed that roughly
a
c d
b
Figure 1 | CT scan of the abdomen and biopsy of skin and kidney. (a) Computer tomography scan of the abdomen shows significant
thickening and edema of jejunum (arrow) (60 60 mm (300 300 DPI)). (b) The skin biopsy shows leukocytoclastic vasculitis. The dermal small
vessels display endothelial cell swelling (arrowhead) and are infiltrated and surrounded by neutrophils, many of which show fragmentation
of nuclei (karyorrhexis) (arrows) (hematoxylin–eosin (H&E), original magnification  600). (c) A glomerulus shows compression of the tuft
by a segmental cellular crescent (arrow) admixed with fibrin (arrowhead). The underlying tuft exhibits mild segmental mesangial
hypercellularity (H&E, original magnification  600). (d) On immunofluorescence, there is intense positivity for IgA in a global mesangial
distribution (original magnification  400).
Table 2 | Major clinical manifestations of HSP seen during the
course of the disease
Symptoms Percentage of patients
Purpura 100
Abdominal pain 63
Gastrointestinal bleeding 33
Arthritis 82
Nephritis 40
HSP, Henoch–Scho¨nlein purpura.
Saulsbury FT. Medicine (Baltimore) 1999; 78:395.
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10% became dialysis dependent at the end of the follow-up.3
It is estimated that 3% of end-stage renal disease in children
is due to HSP. Poor prognostic determinants include hyper-
tension, heavy proteinuria, renal insufficiency, older age,
persistent purpura, crescents in greater than 50% of
glomeruli on biopsy, and low levels of factor XIII.4
Nonrenal manifestations of HSP
Dermatologic features. Purpura is one of the presenting
manifestations in roughly 50% of patients and develops in
96–100% of cases during the course of the disease and is
considered to be a mandatory criterion by many. It begins as
erythematous macules, which turn into purpuric petechiae.
The eruption is symmetric and affects the extensor surfaces of
the lower legs, forearms, and buttocks, and spares the trunk.
Unusual sites to be affected are earlobes, nose, and external
genitalia. Erythema nodosum and blistering lesions are some
of the other skin lesions that may be seen.
Arthritis. Arthralgias and periarticular edema are seen in
60–85% of patients during the course of the disease. Knees,
ankles, elbows, and wrists are commonly affected. Joint mani-
festations may precede the skin findings in 25% of the patients.
Intra-abdominal manifestations
Intra-abdominal manifestations are very common in HSP.
About two-thirds of the patients manifest abdominal pain
(likely owing to local vasculitis), and one-third have occult or
gross gastrointestinal bleeding. The most common surgical
complication of HSP is intussusception.5 In contrast to
idiopathic intussusception, which is ileocolic in more than
80% of children, it is confined to the small bowel in most
cases of HSP.6–8 Other abdominal complications include
acute appendicitis, bowel obstruction secondary to ileus,
bowel ischemia and infarction, perforation of the bowel, and
pancreatitis.5 The correct diagnosis may be difficult to make
when the abdominal complaints precede the onset of rash or
renal involvement, as in this case.
Acute pancreatitis is a rare presentation of HSP.5 It is
presumed to be caused by vasculitic involvement of the
pancreas.9 Most cases of HSP-associated pancreatitis reported
were mild in nature. However, hemorrhagic pancreatitis with
intraperitoneal bleeding has been described.10 Rash usually
precedes the development of pancreatitis. Pancreatitis when
present, develops in the first week of the disease but has
been reported to occur a few weeks to a few months after
the initial presentation.9,11,12 Making the correct diagnosis
is important to avoid unnecessary laparotomy. The diagnosis
can be confirmed by amylasemia and ultrasonography.
Pancreatic pseudocysts are seen in 20% of children with
acute pancreatitis.13 However, they have been reported in
only one case of HSP-associated pancreatitis.14 This may be
due to the fact that HSP-associated pancreatitis is usually
mild. In the absence of renal involvement, the long-term
prognosis is excellent.15 However, if renal impairment is
present, the long-term prognosis depends on the severity
of the glomerular involvement.15
All cases of hepatitis in association with HSP reported
thus far have been in conjunction with viral infections
secondary to hepatitis A, B, and sometimes C.10,12,13 A case
of hepatitis was reported by Cheung et al.14 in 2003
after vaccination for hepatitis B. In our patient, serologic
tests for hepatitis B and C were negative. HSP associated with
hepatitis A is extremely rare, with only five cases reported
so far. Unfortunately, hepatitis A serology was not performed
on our patient.
Myocarditis in HSP
Cardiac involvement, while common in Kawasaki’s disease, is
rare in HSP. Acute rheumatic carditis has been reported in
HSP.15 The clinical symptoms and echocardiographic features
support the diagnosis of carditis in our patient. In all the
cases described in the literature, the diagnosis of rheumatic
carditis was made based on clinical features, EKG, echocar-
diography, and rising antistreptolysin O titers. In most cases,
patients have been reported to recover completely, except for
two who developed valvular lesions.
This patient’s presentation started with an upper respira-
tory tract infection with documented serologic evidence of
group A b-hemolytic streptococcal infection. Whether the
carditis seen here is independent from rheumatic carditis is
debatable, and it is possible that the infection may have
played a role in the pathogenesis of his carditis. Previous
reports of poststreptococcal glomerulonephritis and rheu-
matic carditis in HSP patients support such a possibility.16–18
Follow-up of cardiac findings may help in differentiating the
two conditions.
Treatment of HSP
As mentioned above, complete recovery is seen in approxi-
mately 90% of patients. However, relapse is known to occur
in about 30% of patients. Moderate-dose steroid therapy has
been used for arthritis and gastrointestinal symptoms such as
bleeding and ascites.
Treatment of rapidly progressive or crescentic HSPN. The
outcome of Henoch–Scho¨nlein purpura nephritis (HSPN) is
difficult to determine due to selection bias in treatment.
From unselected series, it appears that the risk of progression
to end-stage renal disease in all children with HSPN is
about 3%. Data on treatment of moderately severe HSPN
are limited by the fact that they are from case series using
historical controls. The evidence available in support of
treatment of rapidly progressive or crescentic HSPN is from
case series with N values of 8–38 patients. There has been no
randomized controlled trial looking at treatment options in
this group. Features suggestive of progression in these studies
are heavy proteinuria and/or nephrotic syndrome and/or
crescentic involvement of 450% of glomeruli. This evidence
is described in detail by Wyatt and Hogg19 and is paraphrased
in Table 3. This article provides the most detailed informa-
tion on evidence-based treatment options in IgA and HSP.
There are no controlled data on the use of angiotensin-
converting enzyme inhibitors and angiotensin receptor
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blockers, but it can be tried early on as a nonspecific
intervention to slow progression of proteinuric renal disease.
The disease can recur in transplanted kidneys in up to
35% of patients at 5 years.20 However, graft loss is rare and
occurs in less than 10% of cases.20
In summary, this case demonstrates the myriad clinical
manifestations of HSP in a single patient. In children, there is
a consensus that it is inappropriate to apply the adult classi-
fication criteria. The working groups of the Pediatric
Rheumatology European Society (PreS), American College
of Rheumatology (ACR), and the European Society of
Paediatric Nephrology (ESPN) have developed consensus
criteria for the childhood vasculitis. According to this,
palpable purpura qualifies for the diagnosis of HSP in
the presence of at least one of the following four features:
diffuse abdominal pain, any biopsy showing predominant
IgA deposition, arthritis or arthralgia, and any renal
involvement (see Table 4). Awareness of the abdominal
manifestations of HSP is important for proper management
and avoidance of unnecessary laparotomy. It is important to
remember that the early outcome depends on the severity of
the various organ involvements. But the long-term outcome
is excellent in the absence of renal involvement.3 Patients
need long-term follow-up as the disease may recur.
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aAcute, any joint.
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